Internationally, DSIP is not formally approved as a drug in the EU, UK, Canada, or Australia
Our doctors provide honest advice in every case, and if a treatment is not suitable, the patient is informed directly
It is administered as an injection and approved for use in adults and children aged 12 years or more with obesity (BMI 30 for adults, BMI 95th percentile for age and sex for children) or adults with overweight who also have weight-related medical problems
Gut diversity as a marker for metformin responsiveness Microbes can influence drug pharmacokinetics through mechanisms such as activation, competition, biodegradation, and potentiation
The sublingual route provides dual benefits: systemic absorption through the bloodstream plus direct mucosal contact with the upper GI tract as residual amounts are swallowed